Case of a Diffuse Large B-Cell Lymphoma Patient Treated with Traditional Korean Medicine Treatment

미만성 거대 B세포 림프종 환자의 한의약치료 증례보고

  • Kim, In Soo (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Cheong, Min Sung (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Oh, Hyun Seung (Department of Internal Medicine, College of Korean Medicine, Dong Shin University) ;
  • Lee, Young Su (Department of Internal Medicine, College of Korean Medicine, Dong Shin University)
  • 김인수 (동신대학교 광주한방병원 내과학교실) ;
  • 정민성 (동신대학교 광주한방병원 내과학교실) ;
  • 오현승 (동신대학교 광주한방병원 내과학교실) ;
  • 이영수 (동신대학교 광주한방병원 내과학교실)
  • Received : 2013.10.22
  • Accepted : 2014.03.18
  • Published : 2014.04.25


This case report that the therapeutic effects of traditional Korean medicine(TKM) treatment on the tumor response in a diffuse large B-cell lymphoma(DLBL) patient. A patient was treated by acupuncture, pharmacopuncture, moxibustion, cupping and herbal medicine once a week at least for 12 months. we evaluated the grade of chief complaints and performed blood tests and sonography, abdominal CT periodically. After 1 month administration with TKM treatment, the symptoms of the patient vanished obviously. the size of inguinal lymphoma decreased gradually through 3 months. then from 3 to 10 months, the size of inguinal lymphoma remained as it is. TKM treatment was maintained continuously. in the abdomino-pelvic CT performed after 12 months, the patient didn't complain any symptom and the size of inguinal lymphoma decreased a little again. This case study supports that TKM treatments may have a efficacy in treating diffuse large B-cell lymphoma(DLBL) patients.


  1. The Non-Hodgkin's Lymphomal Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89: 3909-3918, 1997.
  2. 한지숙, 고윤웅, 민유홍 외 30인. 한국의 악성림프종에 관한 통계적관찰. 대한혈액학회지, 30: 197-203, 1995.
  3. Smith, A., Howell, D., Patmore, R., Jack, A., Roman, E. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. British Journal of Cancer, 105(11):1684-1692, 2001.
  4. Smith, A., Howell, D., Patmore, R., Jack, A., Roman, E. Haematological Malignancy Research Network. British Journal of Haematology, 148(5):739-753, 2010.
  5. Arnold S. Freeman, Jon, C. Aster Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. 2012.
  6. Swerdlow, S.H., Campo, E., Harris, N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Lyon, pp 233-237, 2008.
  7. Sehn, L.H., Berry, B., Chhanabhai, M., et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Blood, 109: 1857-1861, 2007.
  8. 김현정, 홍대식. 미만성 거대 B세포 림프종의 포괄적 고찰. Journal of Soonchunhyang Medical Science, 14(3):467-476, 2009.
  9. Giantonio, B.J., Forastiere, A.A., Comis, R.L. The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care : over 50 years of progress through clinical research. Semin Oncol, 35(5):494-506, 2008.
  10. 박재갑, 박찬일, 김노경. 종양학(Oncology). 서울, 일조각, p 772, 2009.
  11. Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R.S., Kuppes, R., Dalla-Favera, R. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature, 412: 341-346, 2001.
  12. Sweet, D.L., Gaeke, M.E., Golomb, H.M., Ferguson, D.L., Ultmann, J.E. Survival of patients with localized diffuse histiocytic lymphoma. Blood, 58: 1218-1223, 1981.
  13. Nissen, N.I., Ersboll, J., Hansen, H.S., Walbom-Jorgensen, S., Pedersen-Hjergaard, J., Hansen, M.M., Rygard, J.A. randomized study of radiotherapy alone compared with chemotherapy versus radiotherapy plus chemotherapy in stage I-II non0hodgkin's lymphomas. Cancer, 52: 1-7, 1980.
  14. Coiffier, B., Lepage, E., Briere, J., et al. CHOP chemotherapy plus rituximalb compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346: 235-242, 2002.
  15. Fisher, R.I., Gaynor, E.R., Dahlberg, S., et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regiments for advanced non-Hodgkin's lymphoma. Nengl J Med, 328: 1002-1006, 1993.
  16. Feugier, P., Van Hoof, A., Sebban, C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J clin Oncol, 23: 4117-4126, 2005.
  17. Pfeundschuh, M., Trumper, L., Kloess, M., et al. Two-weekly or 3-weekly CHOP cheomtherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104: 634-641, 2004.
  18. 홍성일. 인간 암세포주에 대한 건칠 추출물의 선택적 세포 독성효과. 가천대학교 박사학위. 2007.
  19. 김재용, 정은정, 원영선, 이주혜, 신동영, 서권일. 인체 대장암 세포주 SW480에서 재배 와송의 세포 사멸 유도 효과. 한국식품과학회지 44(3):317-323, 2012.
  20. 김진성, 윤상협, 류봉하, 류기원. 와송의 수종 암세포에 대한 항암작용 연구. 대한한방내과학회지, 26(2):333-340, 2005.
  21. 임좌빈. 와송(瓦松)이 암에 미치는 효능. 대한한의학회지 4(1) 1996.
  22. 윤경수, 김영철, 이장훈, 우홍정. 瓦松이 만성 골수성 백혈병 세포주(K562)에서 세포사멸에 미치는 영향. 대한한방내과학회지 27(1):166-177, 2006.
  23. 박승찬. Akt 활성억제 및 Caspase-3의 활성화를 통한 삼칠근 열수 추출물의 인간 폐암세포에서의 세포사멸 유도. 대전대학교 박사학위. 2009.
  24. Savage, K.J., Harris, N.L., Vose, J.M., ALK-ana-plastic large-cell lymphoma is clinically and im-munopheno-typically different from both ALK+ALCL and peripheral T-cell lymphoma, not other-wise specified: report form the International Peripheral T-cell Lymphoma Project. Blood, 111(12):5496-5504, 2008.
  25. 김시내, 채의수, 김종광, 문준호, 이수정, 김윤정, 이유진, 손상균. 미만성 거대 B세포 림프종 환자 치료 후 절대 림프구 수 감소율의 예후적 가치. 대한내과학회지 76(1):52-59, 2009.